VA
KYMR icon

Vident Advisory’s Kymera Therapeutics KYMR Stock Holding History

Vident Advisory’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
9,028
+586
+7% +$50.4K 0.01% 951
2026
Q1 		$703K Buy
8,442
+861
+11% +$68.2K 0.01% 1061
2025
Q4 		$590K Buy
7,581
+465
+7% +$31.4K 0.01% 1078
2025
Q3 		$403K Sell
7,116
-1,490
-17% -$67.2K ﹤0.01% 1281
2025
Q2 		$376K Buy
+8,606
New +$296K ﹤0.01% 1200
2025
Q1 		– Sell
-5,863
Closed -$236K – 1600
2024
Q4 		$236K Buy
+5,863
New +$265K ﹤0.01% 1259

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vident Advisory's KYMR Position: Q2 2026 in Review

Vident Advisory increased its Kymera Therapeutics (KYMR) stake by 6.9% in Q2 2026, buying an estimated $50.4K and bringing the position to 9,028 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #951.

Vident Advisory first reported a position in KYMR in Q4 2024 and has held it in 6 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Vident Advisory held 9,028 shares of Kymera Therapeutics worth $1.04M as of Q2 2026.
  • Vident Advisory bought 586 Kymera Therapeutics shares in Q2 2026, an estimated $50.4K.
  • Kymera Therapeutics made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #951 holding.
  • Vident Advisory first reported a position in Kymera Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.